Clinical trial · Observational
Prostate-Specific Membrane Antigen (PSMA) Radionuclide Therapy
Prostate-Specific Membrane Antigen (PSMA) Radionuclide Therapy for the Treatment of Metastatic Castration-Resistant Prostate Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): So far, we have not been able to collect meaningful data for these patients which also led to our decision to close this study before attempting write up and publish any results
Summary
Brief summary (as posted)
This study is a single-center registry study collecting clinical data regarding the treatment of PSMA-positive metastatic castration-resistant prostate cancer treated with PSMA radionuclide therapy per the treating physician's discretion. Clinical data from candidates for or who undergo the PSMA procedure at Methodist Dallas Medical Center from August 2022 to August 2027 will be collected after discharge and patients will undergo clinical follow-up per the treating physician's discretion.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| PSMA radionuclide therapy | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- collect clinical data related to treatment of PSMA-positive metastatic castration-resistant prostate cancer
- timeFrame
- Clinical data from candidates for or who undergo the PSMA procedure at Methodist Dallas Medical Center from August 2022 to August 2027 will be collected after discharge and patients will undergo clinical follow-up per the treating physician's discretion
- description
- To collect clinical data related to patient characteristics, treatment responses and survival outcomes related to the treatment of PSMA-positive metastatic castration-resistant prostate cancer treated with PSMA radionuclide therapy
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria:
* 1\. \>18 years of age
* 2\. Diagnosed with PSMA-positive metastatic castration-resistant prostate cancer and - has consented to undergo PSMA nuclear therapy per the treating physician. Specifically:
* Metastatic or Locally Advanced AND Inoperable
* Clear disease progression on PSMA-PET/CT
* PSMA-PET/CT scan positive disease within 6 weeks
* Labs:
* Hemoglobin: \>8 g/dL
* White blood cell count: \>2K cells/µL
* Platelet (Thrombocyte) count: \>75 x 109/L
* No prior therapy with Radium-223 Dichloride
Exclusion Criteria:
* Patients who do not meet the Inclusion Criteria laid out in section 4.2 will be excluded from the study.References
Publications (0)
Data not yet available